ImmunityBio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong ...
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02235688
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02235701
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT02200757
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States
🇺🇸Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸Oncology Hermatology Care, Inc., Cincinnati, Ohio, United States
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 596
- Registration Number
- NCT02138734
- Locations
- 🇺🇸
Skyline Sherman Oaks, Sherman Oaks, California, United States
🇺🇸Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, United States
🇺🇸Hoag Cancer Center, Irvine, California, United States
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 433
- Registration Number
- NCT02049905
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇺🇸The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸Fletcher Allen Health Care, Burlington, Vermont, United States
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02029430
- Locations
- 🇺🇸
Louisiana State University Health Science Center, New Orleans, Louisiana, United States
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02014844
- Locations
- 🇺🇸
Ochsner Health System, New Orleans, Louisiana, United States
🇺🇸Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Texas Oncology-Austin Midtown, Austin, Texas, United States
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01706835
- Locations
- 🇺🇸
Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01673438
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01580397
- Locations
- 🇺🇸
Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders, Milwaukee, Wisconsin, United States
🇺🇸Scottsdale Healthcare, Scottsdale, Arizona, United States